Advertisement

Search Results

Advertisement



Your search for DAWN L. HERSHMAN, MD, MS, FASCO matches 13 pages

Showing 1 - 13


breast cancer

ASCO Awarded $11 Million to Study Oral Drug Dosing Strategies in Older Adults With Metastatic Breast Cancer Receiving CDK4/6 Inhibitors

ASCO has been awarded $11 million in research funding by the Patient-Centered Outcomes Research Institute (PCORI) to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer. The study aims to address a critical evidence gap in the treatment of this...

supportive care
symptom management

Managing Primary Prophylactic Colony-Stimulating Factor Use in Patients Receiving Regimens Associated With Intermediate Risk for Febrile Neutropenia

In a study reported in the Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, FASCO, and colleagues found that a standing order entry (SOE) for vs an alert against use of primary prophylactic colony-stimulating factor (PP-CSF) for patients receiving first-line regimens for cancer associated...

breast cancer
immunotherapy

ASCO Guideline Rapid Update Addresses the Use of Neoadjuvant Pembrolizumab in High-Risk Early-Stage Triple-Negative Breast Cancer

A rapid update to the ASCO Guideline on neoadjuvant therapy for breast cancer adds a recommendation on the use of pembrolizumab in patients with high-risk early-stage triple-negative breast cancer.1 The update follows a recent analysis from the randomized phase III KEYNOTE-522 trial that showed a...

solid tumors
cardio-oncology

Shared Risk Factors for Preventing Cancer and Cardiovascular Disease: The Evolving Focus of Cardio-oncology

Cardio-oncology represents the intersection of cancer and cardiovascular disease. Cancer therapies can result in cardiovascular complications, and some patients become less attentive to their chronic disease management after a diagnosis of cancer. As cancer patients are living longer, for some,...

supportive care
symptom management

Updated ASCO Guideline Revisits Evidence on Prevention and Treatment of Chemotherapy-Induced Neuropathy

Peripheral neuropathy is one of the most prominent chronic side effects of chemotherapy and can linger for years, causing discomfort as well as impaired functionality and quality of life. Yet oncologists have struggled to identify definitive treatment and prevention strategies. In an effort to help ...

Conquer Cancer Names 2020 Women Who Conquer Cancer Mentorship Award Recipients

Conquer Cancer, the ASCO Foundation®, has named Dawn L. Hershman, MD, MS, FASCO, as the 2020 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award recipient, and Lillian L. Siu, MD, FRCPC, FASCO, as the International Women Who Conquer Cancer Mentorship Award recipient. The 2020 Women Who ...

ASCO, Conquer Cancer Honor Leaders in Cancer Care With 2020 Special Awards

ASCO and Conquer Cancer, the ASCO Foundation®, are proud to recognize the winners of ASCO’s 2020 Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. David A. Karnofsky Memorial Award...

integrative oncology

Society for Integrative Oncology’s 16th International Conference

The Society for Integrative Oncology (SIO) hosted its 16th International Conference in New York City, October 19-21, 2019, in partnership with Memorial Sloan Kettering Cancer Center (MSK). The conference theme, “Advancing the Science and Art of Integrative Oncology,” focused on deepening the...

2016 ASCO Annual Meeting Planning Committees

The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with nearly 30,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees and thank them for their time and...

ASCO Recognizes 2016 Recipients of FASCO Distinction

�� The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, patients with cancer.  The 2016...

2016 Special Awards: Researchers and Scientists Recognized for Significant Contributions to Cancer Care

Researchers, patient advocates, and global oncology community leaders dedicated to enhancing cancer prevention, treatment, and patient care will be honored with ASCO’s highest honor, its Special Awards, during the 2016 ASCO Annual Meeting. Among this year’s awardees are a lung cancer luminary who...

2015 ASCO Annual Meeting Planning Committees

The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with more than 28,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees, and thank them for their time and ...

ASCO, Conquer Cancer Foundation Congratulate 2015 Grant and Award Recipients

The Conquer Cancer Foundation of ASCO presented more than $6.7 million in grants and awards to more than 200 promising oncology researchers at the 2015 ASCO Annual Meeting. The Conquer Cancer Foundation and ASCO congratulate the recipients on their contributions to the field of oncology and offer...

Advertisement

Advertisement




Advertisement